Auxilium adopts poison pill, reaffirms QLT deal after Endo offer
This article was originally published in Scrip
Auxilium Pharmaceuticals remained committed to its merger with QLT and adopted a "poison pill" to prevent a takeover after it received Endo International's unsolicited $2.2bn buyout offer, which Auxilium said its board of directors will review in consultation with the company's legal and financial advisors.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.